Unlike for irAEs, IL-6 significantly dichotomized patients at increased risk for cancer-specific and all-cause mortality at a much higher optimal cutoff of 2.3 fold change (Figure 6, C and D; P < 0.001), revealing that the subset of patients with the highest increase in IL-6 was at a disparate risk of early death. Here, IL6 is linked to cancer.